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Photodynamic therapy (PDT) is a promising new treatment
modality for cancer using photosensitizers and light irradiation
(Dougherty et al, 1975). In addition, the fluorescence of photosen-
sitizing chromophores has been proposed to be used in the visual-
ization of early-stage cancers (Kriegmair et al, 1996).
The endogenous conversion of 5-aminolaevulinic acid (ALA) to
protoporphyrin IX (PpIX) has broadened the use of PDT. ALA is
frequently applied topically or systemically in PDT of skin
tumours (Kennedy et al, 1990; Grant et al, 1993; Wolf et al, 1993).
Kennedy et al (1990) have found that ALA in aqueous solution
passed readily through abnormal human skin, but not through
normal keratin.
In the cystosol two molecules of ALA are combined to form
porphobilinogen (PBG) and four molecules of PBG are then
bound to form uroporphyrinogen. Next, uroporphyrinogen is
converted to coproporphyrinogen, which is taken up by mito-
chondria to form PpIX. ALA-induced PpIX accumulation has
been shown to be preferentially greater in certain tumoural cells
(Batlle et al, 1975; Navone et al, 1988; Fukuda et al, 1989)
primarily due to the reduced activity of ferrochelatase, the enzyme
responsible for the conversion of PpIX into haem (Dailey
and Smith, 1984; Van Hillesberg et al, 1992) and a relative
enhancement of deaminase activity (Schoenfeld et al, 1988;
Navone et al, 1991), which constitutes the biological rationale for
the clinical use of the so called ALA-based PDT (ALA-PDT).
PpIX is thought to be the predominant PDT-relevant metabolite
formed from the applied ALA (Schoenfeld et al, 1994), although
other porphyrins may be potent photosensitizers too (Menon et al,
1990; Fukuda et al, 1992).
Little is known concerning the kinetics of tissue uptake and
localization of the porphyrins induced by ALA in vivo after
topical application of the precursor on the tumour, neither is there
any report on porphyrin and precursor excretion after topical ALA
in mice. The aim of this work was to determine the kinetics of
porphyrin generation in tissues after topical application of ALA
delivered in different vehicles on the tumour and normal skin
of mice.
MATERIALS AND METHODS
Chemicals
ALA was purchased from Sigma Chemical Co., St Louis, MO,
USA. All other chemicals were of analytical grade.
Animals
Male BALB/c mice 12 weeks old, weighing 20—25 g were used.
They were provided with food (Purina 3, Molinos R￿o de la Plata,
Argentina) and water ad libitum. A mammary adenocarcinoma
(Scolnik et al, 1984) (M2, Hospital Roffo, Buenos Aires,
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ArgentinaArgentina) was propagated by serial transplantation into male
BALB/c mice. Experiments were performed at day 12 after
implantation. Tumours of the same uniform size were employed.
Animals received human care and were treated in accordance with
guidelines established by the Animal Care and Use Committee of
the Argentine Association of Specialists in Laboratory Animals
(AADEALC), in full accord with the UK Guidelines for the
Welfare of Animals in Experimental Neoplasia (UKCCCR, 1988).
Preparation of ALA
The hydrochloric acid (HCl) salt of ALA was dissolved in sterile
saline at a concentration of 100 mg ml—1 (lotion) or in a 20%
formulation in a base cream (Genargen, Argentina) just prior to
application. The pH of both ALA cream and lotion was 3.5.
ALA administration
For pharmacokinetics of ALA-induced porphyrins, mice received
either 10 mg ALA (50 mg of 20% ALA cream) or 15 mg (0.15 ml
of 100 mg ALA per ml lotion). Both ALA formulations were
applied either on the skin overlying the tumour or on an area of
2.2 cm2 of normal skin, having shaved the hair, rubbing with a
smooth paintbrush for a period of 180 s. At different times up to
24 h after ALA administration (three mice for each point) the
animals were killed by cervical dislocation.
For dose—response kinetic experiments, 50 mg of a cream
containing 10, 20, 30 or 40% ALA or 0.1 ml of a 50, 100, 150 or
200 mg ALA per ml lotion were applied either on the skin over-
lying the tumour or on the normal skin, contralateral to the tumour,
delivering a total amount of 5, 10, 15 and 20 mg ALA. Mice were
killed 3 h after ALA administration (three mice for each point).
Blood was extracted and tumour, skin (contralateral of the tumour
side), skin overlying the tumour, liver, kidney and spleen were
removed and maintained at 0°C until extraction of porphyrins.
Tissue extraction of porphyrins
Before killing, mice were injected with heparin (0.15 ml, 100 UI)
and after sacrifice, they were perfused with 200 ml of sterile
saline. The tissue samples were homogenized in a 4:1 solution of
ethyl acetate—glacial acetic acid mixture (1:5 or 1:10 w/v). Blood
samples were heparinized and vigorously vortexed with the same
extraction solvents. The mixtures were centrifuged for
30 min at 3000 g, and the supernatants were added with an equal
volume of HCl 5%. Extraction with HCl was repeated until there
was no detectable fluorescence in the organic layer. The aqueous
fraction was used for the spectrophotometric determination of
porphyrins. The sum of absorptions at 380 and 430 nm was
substracted from twice the Soret band maximum, and the differ-
ence, divided by a correction factor for Uroporphyrin (Falk, 1964).
A standard of Uroporphyrin I was used as reference.
Porphyrins and precursors determinations in urine
The concentration of total porphyrins and precursors in urine were
determined by column elution and subsequent spectrophoto-
metrical measurement according to the methods of Doss and
Schmidt (1971a, 1971b).
Porphyrin determination in faeces
The content of total porphyrins in faeces was determined spec-
trophotometrically according to Batlle and Grinstein (1962) after
extraction with chloroform of the esterified porphyrins (With,
1975).
Statistical analysis
The unpaired t-test was used to established the significance of
differences between groups. Differences were considered statisti-
cally significant when P < 0.05.
RESULTS
The time course of porphyrin levels in tissues, after topical appli-
cation of ALA on skin overlying the tumour are shown in Figures
1, 2 and 3. Maximal accumulation was found in tumour 3 h after
ALA application in both cream and lotion (Figure 1). Normal and
overlying tumour skin tissues showed different kinetic patterns.
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Figure 1 Concentration of ALA-induced porphyrins in tumour, normal skin
and skin overlying the tumour as a function of time after topical application of
ALA in cream and lotion on the skin overlying the tumour. At different times
after topical application of 10 mg ALA in cream (l l) or 15 mg in lotion (D) on
the skin overlying the tumour, the tissues were excised and porphyrins
extracted as detailed in Materials and Methods. Each data point represents
the average of three determinations. Error bars show standard deviationsWhile ALA cream-induced porphyrins peaked in normal skin at
1.5 h after application, ALA lotion produced a broad peak between
3 and 8 h. Conversely, peak levels in skin overlying the tumour
were reached at 3 and 8 h after ALA lotion and cream application
respectively.
Figure 2 depicts kinetic profiles in liver, spleen and kidney.
Liver exhibits a maximum accumulation of tetrapyrroles at 3 h and
8 h after cream and lotion application respectively, spleen and
kidney show nearly coincident peaks at about 5 h for both vehicles
of ALA.
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Figure 2 Concentration of ALA-induced porphyrins in liver, spleen and
kidney as a function of time after topical application of ALA in cream and
lotion on skin overlying the tumour. At different times after topical application
of 10 mg ALA in cream (l l) or 15 mg in lotion (D) on the skin overlying the
tumour, the tissues were excised and porphyrins extracted as detailed in
Materials and Methods. Each data point represents the average of three
determinations. Error bars show standard deviations.
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Figure 3 Concentration of ALA-induced porphyrins in blood as a function of
time after topical application of ALA in cream and lotion on the skin overlying
the tumour. At different times after tumour topical application of 10 mg ALA in
cream (l l) or 15 mg in lotion (D) on the skin overlying the tumour, heparinized
blood was extracted for porphyrin determinations as detailed in Materials and
Methods. Each data point represents the average of three determinations.
Error bars show standard deviations
 ALA (mg)
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Figure 4 Porphyrin accumulation in tumour, skin and skin overlying the
tumour after topical application on the skin overlying the tumour and normal
skin of various quantities of ALA. Different amounts of ALA cream were
applied on the skin overlying the tumour (l l), or normal skin (l) and of ALA
lotion on the skin overlying the tumour (D) and normal skin (s). Three hours
later, tissues were excised and porphyrins extracted as detailed in Materials
and Methods. Each data point represents the average of three
determinations. Error bars show standard deviations.
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Figure 5 Porphyrin accumulation in liver after topical application on the skin
overlying the tumour and normal skin of various quantities of ALA. Different
amounts of ALA cream were applied on the skin overlying the tumour (l l), or
normal skin (l) and of ALA lotion on the skin overlying the tumour (D) and
normal skin (s). Three hours later, livers were excised and porphyrins
extracted as detailed in Materials and Methods. Each data point represents
the average of three determinations. Error bars show standard deviationsPorphyrin levels always return to normal values within 24 h of
ALA topical application whichever vehicle was employed.
Blood porphyrin values (Figure 3) found its maximum at 3 h
and then fell to basal levels when cream vehicle was employed. A
slight increase was observed at 24 h after ALA lotion application.
The dose course of porphyrin levels in tissues after cream and
lotion application of ALA on either skin overlying the tumour or
normal skin are shown in Figures 4, 5 and 6. In tumour, skin and
skin overlying the tumour (Figure 4), maximum levels were higher
when ALA was applied in lotion on skin overlying the tumour.
Porphyrin formation reached a plateau in tumour between 10 mg
and 15 mg of ALA when either ALA lotion or cream were applied.
Tumoural porphyrins induced when ALA was applied on normal
skin peaked at 20 mg and 10 mg for lotion and cream respectively.
In skin, ALA lotion induced higher accumulation than ALA
cream. In skin overlying the tumour maximal values were obtained
when ALA lotion was applied on it.
Figure 5 shows that maximal liver porphyrin accumulation was
obtained after topical application of ALA lotion on the normal
skin. High amounts of tetrapyrroles were also formed after appli-
cation of ALA cream on skin overlying the tumour, in both cases
yielding a saturation point at 10 mg ALA.
Figure 6 represents the total amount of porphyrins accumulated
in all tissues analysed. Both cream and lotion applied on normal
skin induced increasing levels of tissue porphyrins while
increasing the dose of ALA, but when applied on the skin over-
lying the tumour, the values decreased with high ALA doses,
reflecting a saturation pattern. Higher total amounts of porphyrins
were formed after application of ALA lotion on skin overlying the
tumour and in normal skin.
Table 1 shows total excretion of porphyrins during the first 24 h
after ALA lotion application on skin overlying the tumour, an
increase from 0.084 to 1.82 mg in urine and from 35.34 to 93.88 mg
in faeces of ALA-treated animals compared to the controls was
found; 24 to 48 h after ALA application values returned nearly to
basal levels.
Table 2 shows total excretion of precursors during the first 24 h
after ALA application. Whereas precursor levels are undetectable
in control mice, after topical application of ALA lotion values
raise to 3.61 mg for ALA and 39.48 mg for PBG; 24—48 h after
ALA application, precursor levels were again undetectable.
DISCUSSION
Topical application of ALA lotion on skin overlying the tumour,
induced peaks of porphyrin accumulation in tumour and skin over-
lying the tumour 3 h after treatment, in agreement with Peng et al
(1992) and Henderson et al (1995), who have found that ALA-
induced porphyrins in murine adenocarcinomas peaked between
3 and 5 h post-application. We have found that administration of
15 mg ALA lotion, formed nearly 2 mg porphyrins g—1 tissue, twice
the amount reported by Peng et al (1992) using a 20% ALA cream
in a mammary adenocarcinoma. These porphyrins may then reach
spleen and kidney at 5 h, as can be deduced from its delayed peak
in these tissues. Peak porphyrin levels in liver and skin were found
even later (8 h). Apparently, high amounts of porphyrins are
synthesized in the liver, which can then be redistributed and
accumulated in skin tissue.
In line with these results, Fukuda et al (1992) and Peng et al
(1992) reported that after intraperitoneal ALA administration,
peak porphyrin levels are found in tumour at shorter intervals than
in liver, indicating that tumoural cells are capable of synthesizing
the endogenous porphyrins themselves.
Spleen and kidney did not show a second peak after 8 h,
showing that liver porphyrins had already been excreted and did
not accumulate in these tissues. A rise in blood porphyrin levels
at 24 h supports the hypothesis that liver porphyrins are being
eliminated.
A dynamic flow of porphyrins is highly probable, given the
serum porphyrin-binding molecules and the ease at which ALA-
induced porphyrins can exit from tissue (Fukuda et al, 1993;
Henderson et al, 1995). However, it cannot be ruled out the possi-
bility that ALA itself has reservoir compartments such as the
16 A Casas et al
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Figure 6 Total porphyrin accumulation after topical application in the skin
overlying the tumour and normal skin of different amounts of ALA. Three
hours after application of varying amounts of ALA cream on the skin overlying
the tumour ( ), or normal skin ( ) and of ALA lotion on the skin overlying
the tumour ( ) and normal skin (n n), the sum of porphyrin concentrations in
skin, tumour, skin overlying the tumour, kidney, liver, spleen and blood were
depicted
Table 1 Porphyrin excretion after topical application of ALA on the skin
overlying the tumour
Urine Faeces
Control 0.084 ± 0.009 35.34 ± 5.50
Topical ALA 1.82 ± 0.12 93.88 ± 7.32
Total amount of porphyrins in mg excreted in 24 h per mice after application
of 15 mg of ALA lotion on the skin overlying the tumour.
Table 2 Precursors excretion after topical application of ALA on the skin
overlying the tumour
ALA PBG
Control ND ND
Topical ALA 3.61 ± 0.45 39.48 ± 8.04
Total amount of ALA and PBG in mg excreted in 24 h per mice after
application of 15 mg of ALA lotion on the skin overlying the tumour.
ND: non-detectable.stratum corneum in skin (Rougier and Lotte, 1986) which may
lead to particular kinetic patterns in each tissue.
We have found that high quantities of porphyrins were accumu-
lated in a tumour implanted in the contralateral side of a topically
treated tumour (data not shown), indicating that, if ALA is not
transferred to remote sites by direct contact, an efflux of
porphyrins to distant tumours may exist, very likely through the
bloodstream. Similar results were obtained by Stringer et al
(1996), when psoriasis plaques were treated with ALA and remote
plaques displayed significant fluorescence, afterwards.
Topical application of ALA cream generated lower amounts of
porphyrins than ALA lotion in all tissues. In this case both tumour
and liver porphyrins peak at 3 h, while delayed peaks were
observed in skin overlying the tumour and kidney and no rise was
found in blood porphyrin levels at 24 h. Probably, the amount of
ALA in this vehicle entering into the bloodstream is lower, thus
accounting for the lack of extensive synthesis of liver porphyrins.
Porphyrin synthesis is most efficient in tumour when ALA
lotion is applied. Moreover, it is noteworthy that ALA lotion
applied on normal skin distant from tumour, induced levels of
tumoural porphyrins equal or higher than those induced by ALA
cream directly applied on the skin overlying the tumour. We
hypothesize that ALA penetration is favoured by a hydrophilic
vehicle and that after passing through the stratum corneum and
adnexal structures, reaches the circulation and it is distributed
homogeneously by the tumour microvasculature, so producing
higher porphyrin levels than a lipophilic vehicle.
Similarly, normal skin accumulates higher amount of
porphyrins after application of an ALA lotion on both skin over-
lying the tumour and normal skin, surpassing levels reached with
the cream application directly over the skin, indicating the impor-
tant role of the vehicle. Skin overlying the tumour always showed
similar kinetic patterns as to the tumour, reflecting the histological
changes occurring in this tissue when it is invaded by tumour cells.
In all tissues analysed ALA lotion on normal skin produced
saturation patterns with high quantities of ALA (20 mg) as
compared to its application on skin overlying the tumour, probably
because of the larger retention of porphyrins in tumour, allowing a
lesser amount of ALA to be distributed among the rest of the
tissues.
The sum of porphyrins accumulated in all tissues shows that
maximal porphyrin values are formed when ALA is applied in the
lotion formulation. This assures a better penetration and distribu-
tion after passing through both normal and overlying tumour skins.
Indeed, the fact that maximal values are reached after application
on normal skin indicates that ALA would be penetrating easier
normal skin than invaded overlying tumour skin.
Results indicate that in control mice, porphyrins are mostly
eliminated by faeces (35.34 mg against 0.084 mg measured in
urine), but in ALA-topically treated animals, control values
increase three times in faeces and 21 times in urine, showing that
hydrophilic porphyrins (uroporphyrins) are formed and more
rapidly eliminated in this way. From the precursor excretion
profiles we can also speculate that PBG deaminase and not ALA
dehydrase is the limiting enzyme in the conversion of ALA to
porphyrins.
Intratumour and i.p. administration of ALA in the same adeno-
carcinoma gave different kinetic biodistribution profiles and total
amounts of ALA-derived porphyrins in tissues (Fukuda et al,
1992), showing that the route of ALA administration strongly
affects tetrapyrrole synthesis, distribution and elimination patterns.
In contrast to Kennedy et al (1990) findings about the relative
impermeability of the normal human skin to ALA and Fritsch et al
(1996) who reported lack of increase of either porphyrins or
precursors in urine and blood of topically treated patients, we have
found that ALA is capable of penetrating normal mouse skin, to
enter the bloodstream and reach the tissues. Moreover, it is thought
that keratin, due to its fibrilar structure, may exist in two phases:
one polar and another apolar; the former enriched in water is actu-
ally contained into the latter. This may account for penetration of
hydrophilic substances such as ALA into the stratum corneum
(Torralba Rodr￿guez, 1985).
The small size of the animal used, the thin epidermis, the higher
density of hair follicles and the relative large body surface covered
by the ALA formulation may explain the differences observed
between human and mice response. These differences must be
taken into account when extrapolating time and dose schedules to
human studies. Moreover, BALB/c albino mice skin may be less
resistant to penetration of ALA, in the same way that the more fair
and thin human skins allow quite significant penetration of ALA
(Kennedy and Pottier, 1992). This may also explain the results of
Goff et al (1992), who found no evidence of PpIX fluorescence in
hairless guinea pig skin exposed to topical ALA.
Penetration of ALA appears to be greatly influenced by the
vehicle, and may be the result of penetration of ALA through the
stratum corneum either by diffusion or active transport or direct
passage to the dermis via adnexal structures, as it was reported for
polar penetrants (Magee, 1991).
We have presented here strong evidence for the great influence
of the formulation of ALA vehicle on its penetration through the
skin. Knowledge of the kinetics of porphyrin generation after
different conditions of ALA application is important for the
optimization of diagnosis and phototherapy of human tumours by
means of ALA-PDT.
ACKNOWLEDGEMENTS
This research was supported by grants from the Argentine
National Research Council (CONICET), the Association for
International Cancer Research (AICR)-UK and the Alberto J
Roemmers Foundation, Argentine. The authors are very grateful to
Mrs Victoria Castillo for her skillful technical assistance. AM del
CB and HF hold the posts of Superior and Associate Researchers
at the CONICET. AC is a CONICET Research Fellow.
REFERENCES
Batlle A and Grinstein M (1962) Porphyrin biosynthesis. Studies on the nature of a
biosynthetic porphyrin and its identification with the so-called ￿208￿
porphyrin. Biochim Biophys Acta 57: 191—194
Batlle A, Llamb￿as E, Wider E and Tigier H (1975) Porphyrin biosynthesis in the
soybean callus tissue system XV. The effect of growth conditions. Int J
Biochem 6: 591—606
Dailey H and Smith A (1984) Differential interaction of porphyrins used in
photoradiation therapy with ferrochelatase. Biochem J 223: 441—445
Doss M and Schmidt A (1971a) Rapid determination of urinary total porphyrins by
ion exchange chromatography. Z Klin Chem Klin Biochem 9: 415—418
Doss M and Schmidt A (1971b) Quantitative Bestimmung der 5-Aminol￿vulins￿ure
und Porphobilinogen im Urin mit lonenaustauschercromathographie-
Fertigs￿ulen. Z Klin Chem Klin Biochem 9: 99—102
Dougherty T, Grindey G, Fiel R, Weishaupt K and Boyle D (1975) Photoradiation
therapy II: cure of animal tumours with hematoporphyrin and light. J Natl
Cancer Inst 55: 115—121
Falk J (1964) Porphyrins and metalloporphyrins. In: Biochimica of Biophysica 
Acta-Library Vol. 2. Elsevier: Amsterdam
Tissue distribution of ALA-induced porphyrins 17
British Journal of Cancer (1999) 81(1), 13–18 © 1999 Cancer Research CampaignFritsch C, Verwohlt B, Bolsen K, Ruzicka T and Goerz G (1996) Influence of topical
photodynamic therapy with 5-aminolevulinic acid on porphyrin metabolism.
Arch Dermatol Res 288: 517—521
Fukuda H, Paredes S and Batlle A (1989) Tumour-localizing properties of
porphyrins. In vitro studies using the porphyrin precursor, aminolevulinic acid,
in free and liposome encapsulated forms. Drug Des Deliv 5: 133—139
Fukuda H, Paredes S and Batlle A (1992) Tumour-localizing properties of
porphyrins. In vivo studies using free and liposome encapsulated
aminolevulinic acid. Comp Biochem Physiol 102B: 433—436
Fukuda H, Batlle A and Riley P (1993) Kinetics of porphyrin accumulation in
cultured epithelial cells exposed to ALA. Int J Biochem 25: 1407—1410
Goof B, Bachor R, Kollias N and Hasan T (1992) Effects of photodynamic therapy
with topical application of 5-aminolevulinic acid on normal skin of hairless
guinea pigs. J Photochem Photobiol 15: 239—251
Grant W, Hopper C, MacRobert A, Speight P and Bown S (1993) Photodynamic
therapy of oral cancer: photosensitization with systemic aminolevulinic acid.
Lancet 342: 147—148
Henderson BW, Vaughan L, Bellnier D, Van Leengoed H, Johnson PG and Oseroff
AR (1995) Photosensitization of murine tumour, vasculature and skin by 5-
aminolevulinic acid-induced porphyrin. Photochem Photobiol 62: 780—789
Kennedy J and Pottier R (1992) Endogenous protoporphyrin IX, a clinically useful
photosensitizer for photodynamic therapy. J Photochem Photobiol B 14:
275—292
Kennedy J, Pottier R and Pross G (1990) Photodynamic therapy with endogenous
protoporphyrin IX: basic principles and present clinical experience.
J Photochem Photobiol B 6: 143—148
Kriegmair M, Baumgartner R, Knuechel R, Stepp H, Hofst￿dter F and Hofstetter A
(1996) Detection of early bladder cancer by 5-aminolevulinic acid induced
porphyrin fluorescence J Urology 155: 105—110
Magee P (1991) Percutaneous absorption: critical factors in transdermal transport.
In: Dermatoxicology, Marzulli F and Maibach H (eds) pp. 1—35. Hemisphere:
New York
Menon J, Becker S, Persad S and Haberman H (1990) Quantitation of hydrogen
peroxide formed during UV-visible irradiation of protoporphyrin,
coproporphyrin and uroporphyrin. Clin Chim Acta 186: 375—381
Navone N, Frisardi Resnik E, Batlle A and Polo C (1988) Porphyrin biosynthesis in
human breast cancer. Preliminary mimetic in vitro studies. Med Sci Res 16:
61—62
Navone N, Polo C, Frisardi A and Batlle A (1991) Mouse mammary carcinoma
PBGase and hydroxymethylbilane synthetase. Comp Biochem Physiol B 98:
67—71
Peng Q, Moan J, Warloe T, Nesland JM and Rimington C (1992) Distribution and
photosensitizing efficiency of porphyrins induced by application of exogenous
5-aminolevulinic acid in mice bearing mammary carcinoma. Int J Cancer 52:
433—443
Rougier A and Lotte C (1986) Correlations between horny layer concentration and
percutaneous absorption. In: Pharmacology and Skin: 1. Skin
Pharmacokinetics. Shroot B (ed) Schaeger: Switzerland
Schoenfeld N, Epstein O, Lahav M, Mamet R, Shaklai M and Atsmon A (1988) The
heme biosynthetic pathway in lymphocytes of patients with malignant
lymphoproliferative disorders. Cancer Lett 43: 43—48
Schoenfeld N, Mamet R, Nordenberg Y, Shafran M, Babushkin T and Malik Z
(1994) Protoporphyrin biosynthesis in melanoma B16 cells stimulated by 5-
aminolaevulinic acid and chemical inducers: characterization of photodynamic
inactivation. Int J Cancer 56: 106—112
Scolnik A, Rubio M, Colombo L, Comolli R and Caro R (1984) Further studies on
the hystamine metabolism in the M2 adenocarcinoma. Biomed Pharmacother
38: 465—467
Stringer M, Collins P, Robinson D, Stables G and Sheehan-dare R (1996) The
accumulation of Protoporphyrin IX in plaque psoriasis after topical application
of 5-aminolevulinic acid indicates a potential for superficial photodynamic
therapy. J Invest Dermatol 107: 76—81
Torralba Rodr￿guez A (1985) Histolog￿a y fisiolog￿a de la piel y sus anejos. Aspectos
b￿sicos e implicaciones cosm￿ticas. In: Cosmetología teórico-práctica, pp
13—46. Consejo General de Colegios Oficiales de Farmac￿uticos: Madrid
UK Coordinating Committee on Cancer Research (1988) UKCCCR Guidelines for
the Welfare of Animals in Experimental Neoplasia. UKCCCR: London
Van Hillesberg R, Van der Berg J, Kort W, Terpstra O and Wilson J (1992) Selective
accumulation of endogenously produced porphyrins in a liver metastasis model
in rats. Gastroenterology 103: 647—651
With T (1975) Clinical use of porphyrin ester cromatography in urine and feces. Dan
Med Bull 22: 74
Wolf P, Rieger E and Kerl H (1993) Topical photodynamic therapy with endogenous
porphyrins after application of 5-aminolevulinic acid. J Am Acad Dermatol 28:
17—21
18 A Casas et al
British Journal of Cancer (1999) 81(1), 13–18 © 1999 Cancer Research Campaign